Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19
Enzo Biochem, Inc. ($0.01 Par Value) (ENZ)
Last enzo biochem, inc. ($0.01 par value) earnings: 12/7 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
enzo.com/corporate/investor-information
Company Research
Source: GlobeNewswire
NEW YORK, NY, April 29, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof. The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. In February, Enzo reported the publication of work by academic researchers demonstrating that drug candidate SK1-I decreased Interferon (IFN) signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney, in a chemically induced mouse model of lupus. In more detail, that work demonstrated that SK1-I reduced the levels of inflammatory cytokines including Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF-alpha), and Interferon-alpha and -beta in the animal model. Significantly, elevated level
Show less
Read more
Impact Snapshot
Event Time:
ENZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENZ alerts
High impacting Enzo Biochem, Inc. ($0.01 Par Value) news events
Weekly update
A roundup of the hottest topics
ENZ
News
- Enzo Biochem, Inc. (NYSE: ENZ) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges [Yahoo! Finance]Yahoo! Finance
- Enzo Biochem First Quarter 2025 Earnings: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024) [Yahoo! Finance]Yahoo! Finance
- Enzo Biochem, Inc. (NYSE: ENZ) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update [Yahoo! Finance]Yahoo! Finance
ENZ
Sec Filings
- 12/16/24 - Form 10-Q
- 12/2/24 - Form 3
- 11/29/24 - Form ARS
- ENZ's page on the SEC website